Literature DB >> 22423040

Regulation of foam cells by adenosine.

Allison B Reiss1, Bruce N Cronstein.   

Abstract

Macrophages rely on reverse cholesterol transport mechanisms to rid themselves of excess cholesterol. By reducing accumulation of cholesterol in the artery wall, reverse cholesterol transport slows or prevents development of atherosclerosis. In stable macrophages, efflux mechanisms balance influx mechanisms, and accumulating lipids do not overwhelm the cell. Under atherogenic conditions, inflow of cholesterol exceeds outflow, and the cell is ultimately transformed into a foam cell, the prototypical cell in the atherosclerotic plaque. Adenosine is an endogenous purine nucleoside released from metabolically active cells by facilitated diffusion and generated extracellularly from adenine nucleotides. Under stress conditions, such as hypoxia, a depressed cellular energy state leads to an acute increase in the extracellular concentration of adenosine. Extracellular adenosine interacts with 1 or more of a family of G protein-coupled receptors (A(1), A(2A), A(2B), and A(3)) to modulate the function of nearly all cells and tissues. Modulation of adenosine signaling participates in regulation of reverse cholesterol transport. Of particular note for the development of atherosclerosis, activation of A(2A) receptors dramatically inhibits inflammation and protects against tissue injury. Potent antiatherosclerotic effects of A(2A) receptor stimulation include inhibition of macrophage foam cell transformation and upregulation of the reverse cholesterol transport proteins cholesterol 27-hydroxylase and ATP binding cassette transporter A1. Thus, A(2A) receptor agonists may correct or prevent the adverse effects of inflammatory processes on cellular cholesterol homeostasis. This review focuses on the importance of extracellular adenosine acting at specific receptors as a regulatory mechanism to control the formation of foam cells under conditions of lipid loading.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22423040      PMCID: PMC3306592          DOI: 10.1161/ATVBAHA.111.226878

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  93 in total

Review 1.  CD36 and atherosclerosis.

Authors:  R L Silverstein; M Febbraio
Journal:  Curr Opin Lipidol       Date:  2000-10       Impact factor: 4.776

Review 2.  Atherosclerosis: immune and inflammatory aspects.

Authors:  Allison B Reiss; Amy D Glass
Journal:  J Investig Med       Date:  2006-04       Impact factor: 2.895

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

Review 4.  Shaping of monocyte and macrophage function by adenosine receptors.

Authors:  György Haskó; Pál Pacher; Edwin A Deitch; E Sylvester Vizi
Journal:  Pharmacol Ther       Date:  2006-09-14       Impact factor: 12.310

5.  The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells.

Authors:  Khaled Bshesh; Bin Zhao; Donn Spight; Italo Biaggioni; Igor Feokistov; Alvin Denenberg; Hector R Wong; Thomas P Shanley
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 6.  Reverse cholesterol transport: from classical view to new insights.

Authors:  Astrid-E van der Velde
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 7.  Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Authors:  Alain Tedgui; Ziad Mallat
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

8.  Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages.

Authors:  Allison B Reiss; Mohammad M Rahman; Edwin S L Chan; M Carmen Montesinos; Nahel W Awadallah; Bruce N Cronstein
Journal:  J Leukoc Biol       Date:  2004-06-14       Impact factor: 4.962

9.  Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease.

Authors:  Sam L Stephen; Katie Freestone; Sarah Dunn; Michael W Twigg; Shervanthi Homer-Vanniasinkam; John H Walker; Stephen B Wheatcroft; Sreenivasan Ponnambalam
Journal:  Int J Hypertens       Date:  2010-08-17       Impact factor: 2.420

10.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

View more
  16 in total

1.  Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE-/- (Apolipoprotein E Deficient) Mice.

Authors:  Min Zhang; Xianqiu Zeng; Qiuhua Yang; Jiean Xu; Zhiping Liu; Yaqi Zhou; Yapeng Cao; Xiaoyu Zhang; Xiaofei An; Yiming Xu; Lei Huang; Zhen Han; Tao Wang; Chaodong Wu; David J Fulton; Neal L Weintraub; Mei Hong; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  High-density lipoprotein from subjects with coronary artery disease promotes macrophage foam cell formation: role of scavenger receptor CD36 and ERK/MAPK signaling.

Authors:  S Sini; D Deepa; S Harikrishnan; N Jayakumari
Journal:  Mol Cell Biochem       Date:  2016-12-19       Impact factor: 3.396

Review 4.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

Review 5.  Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Katya Ravid
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

Review 6.  Adenosine and the Cardiovascular System.

Authors:  Allison B Reiss; David Grossfeld; Lora J Kasselman; Heather A Renna; Nicholas A Vernice; Wendy Drewes; Justin Konig; Steven E Carsons; Joshua DeLeon
Journal:  Am J Cardiovasc Drugs       Date:  2019-10       Impact factor: 3.571

Review 7.  The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases.

Authors:  Margarete Dulce Bagatini; Alessandra Antunes Dos Santos; Andréia Machado Cardoso; Aline Mânica; Cristina Ruedell Reschke; Fabiano Barbosa Carvalho
Journal:  J Immunol Res       Date:  2018-08-12       Impact factor: 4.818

8.  Be Aware of Aggregators in the Search for Potential Human ecto-5'-Nucleotidase Inhibitors.

Authors:  Lucas G Viviani; Erika Piccirillo; Arquimedes Cheffer; Leandro de Rezende; Henning Ulrich; Ana Maria Carmona-Ribeiro; Antonia T-do Amaral
Journal:  Molecules       Date:  2018-07-27       Impact factor: 4.411

9.  Nucleotide Catabolism on the Surface of Aortic Valve Xenografts; Effects of Different Decellularization Strategies.

Authors:  Barbara Kutryb-Zajac; Ada H Y Yuen; Zain Khalpey; Paulina Zukowska; Ewa M Slominska; Patricia M Taylor; Steven Goldstein; Albert E Heacox; Marialuisa Lavitrano; Adrian H Chester; Magdi H Yacoub; Ryszard T Smolenski
Journal:  J Cardiovasc Transl Res       Date:  2016-02-01       Impact factor: 4.132

Review 10.  The crosstalk: exosomes and lipid metabolism.

Authors:  Wei Wang; Neng Zhu; Tao Yan; Ya-Ning Shi; Jing Chen; Chan-Juan Zhang; Xue-Jiao Xie; Duan-Fang Liao; Li Qin
Journal:  Cell Commun Signal       Date:  2020-08-03       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.